Home > Oncology > ASCO GU 2022 > Prostate Cancer > Darolutamide improves OS in mHSPC

Darolutamide improves OS in mHSPC

Presented By
Dr Matthew Smith, Massachusetts General Hospital Cancer Center, MA, USA
ASCO GU 2022
Phase 3, ARASENS
In the phase 3 ARASENS trial, the androgen receptor inhibitor darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel improved overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is a highly potent androgen receptor inhibitor that demonstrated improved OS and metastasis-free survival versus placebo in patients with non-metastatic castration-resistant prostate cancer (mCRPC) [1,2]. The current treatment guidelines for mHSPC recommend the addition of docetaxel to ADT in patients who present with M1 disease and are fit for docetaxel. The ARASENS trial (NCT02799602) evaluated whether darolutamide in combination with standard ADT plus docetaxel would increase OS in patients with mHSPC. The study enrolled 1,306 mHSPC patients with a median age of 67 years. Participants were randomised ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on